Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00519285 |
| Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) |
| completed |
| Phase 3 |
| 1,224 |
| SanofiINDUSTRY |
| 31 |
| Jul 22, 2016 |
| clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT00738530 | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | completed | Phase 3 | 649 | Hoffmann-La RocheINDUSTRY | 18 | Jun 23, 2016 | clinicaltrials |
| NCT01494506 | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer(NAPOLI-1) | completed | Phase 3 | 417 | Merrimack PharmaceuticalsINDUSTRY | 15 | Jun 17, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer(VANILLA) | terminated | Phase 3 | 546 | SanofiINDUSTRY | 24 | Jun 7, 2016 | clinicaltrials |
| NCT02777736 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma(CLSG-CNS-001) | unknown | Phase 3 | 500 | Czech Lymphoma Study GroupOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT00259064 | Iressa v BSC (Best Supportive Care) in First Line NSCLC(INSTEP) | completed | Phase 2 / Phase 3 | 216 | AstraZenecaINDUSTRY | 5 | Jun 2, 2016 | clinicaltrials |
| NCT01286077 | Velcade Consolidation Bone Study | completed | Phase 2 | 106 | Janssen-Cilag International NVINDUSTRY | 8 | May 30, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT01350804 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)(NURTURE 1) | completed | Phase 3 | 551 | Novartis PharmaceuticalsINDUSTRY | 15 | May 23, 2016 | clinicaltrials |
| NCT01585649 | PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma | completed | Phase 1 | 21 | Merckle GmbHINDUSTRY | 6 | May 18, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | completed | Phase 2 | 130 | GlaxoSmithKlineINDUSTRY | 13 | Apr 18, 2016 | clinicaltrials |
| NCT01980134 | The MORDIS Study Clinical Investigational Plan(MORDIS) | unknown | — | 1,200 | SpectraScienceOTHER | 5 | Apr 14, 2016 | clinicaltrials |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis(VELVET) | terminated | Phase 2 | 300 | TakedaINDUSTRY | 11 | Apr 13, 2016 | clinicaltrials |
| NCT02041507 | Water-aided Colonoscopy vs Air Insufflation Colonoscopy in Colorectal Cancer Screening | completed | N/A | 1,224 | Presidio Ospedaliero Santa BarbaraOTHER | 3 | Apr 13, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT00338247 | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | approved for marketing | — | — | NovartisINDUSTRY | 45 | Apr 6, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT00320385 | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer | completed | Phase 3 | 296 | GlaxoSmithKlineINDUSTRY | 13 | Feb 26, 2016 | clinicaltrials |
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients(PEN-PV) | completed | Phase 3 | 30 | AOP Orphan Pharmaceuticals AGINDUSTRY | 8 | Feb 17, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT00681122 | CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)(CARIATIDE) | completed | — | 2,600 | AstraZenecaINDUSTRY | 18 | Jan 18, 2016 | clinicaltrials |
| NCT01459653 | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor(Monitor-GCSF) | completed | — | 1,496 | SandozINDUSTRY | 12 | Jan 11, 2016 | clinicaltrials |
| NCT01532453 | Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients | terminated | Phase 3 | 244 | Spirig Pharma Ltd.INDUSTRY | 9 | Jan 8, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
| NCT02637596 | Quality of Life After Radiofrequency Ablation of Pancreatic Cancer | completed | N/A | 1 | Brno University HospitalOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT02025244 | EUS-FNA Versus KHB in Diagnostics of Upper Gastrointestinal Submucosal Tumors | unknown | N/A | 52 | Vitkovice HospitalOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
| NCT02386618 | Endoscopic Treatment for Local Residual Neoplasia | completed | N/A | 25 | Vitkovice HospitalOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials